Which has preferable valuation & earnings, MBX or MNPR?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MBX Biosciences N/A N/A -$86.97M -$2.21 N/A Monopar Therapeutics N/A N/A -$13.72M -$1.90 N/A

Is MBX or MNPR more profitable?

Monopar Therapeutics' return on equity of -12.84% beat MBX Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -26.21% -25.29% Monopar Therapeutics N/A -12.84% -12.57%

Does the media favor MBX or MNPR?

In the previous week, MBX Biosciences had 6 more articles in the media than Monopar Therapeutics. MarketBeat recorded 10 mentions for MBX Biosciences and 4 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.47 beat MBX Biosciences' score of -0.07 indicating that Monopar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Monopar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer RGC or MNPR?

Monopar Therapeutics has a consensus target price of $112.08, indicating a potential downside of 5.98%. Given Monopar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Monopar Therapeutics is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Monopar Therapeutics 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 3.07

Which has stronger valuation and earnings, RGC or MNPR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Monopar Therapeutics N/A N/A -$13.72M -$1.90 N/A

Is RGC or MNPR more profitable?

Regencell Bioscience's return on equity of 0.00% beat Monopar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Monopar Therapeutics N/A -12.84% -12.57%

Which has preferable valuation and earnings, MNPR or IRON?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monopar Therapeutics N/A N/A -$13.72M -$1.90 N/A Disc Medicine N/A N/A -$212.18M -$6.58 N/A

Is MNPR or IRON more profitable?

Monopar Therapeutics' return on equity of -12.84% beat Disc Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -12.84% -12.57% Disc Medicine N/A -37.17% -33.65%

Does the media refer more to MNPR or IRON?

In the previous week, Disc Medicine had 17 more articles in the media than Monopar Therapeutics. MarketBeat recorded 21 mentions for Disc Medicine and 4 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.47 beat Disc Medicine's score of 0.43 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Disc Medicine 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MNPR or RARE?

In the previous week, Ultragenyx Pharmaceutical had 20 more articles in the media than Monopar Therapeutics. MarketBeat recorded 24 mentions for Ultragenyx Pharmaceutical and 4 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.47 beat Ultragenyx Pharmaceutical's score of 0.36 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ultragenyx Pharmaceutical 7 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral

Monopar Therapeutics (MNPR) Competitors

$119.21 -1.00 (-0.83%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$119.04 -0.17 (-0.15%)

As of 08/7/2026 07:34 PM Eastern

Compare

MNPR vs. MBX, RGC, MOR, IRON, and RARE

Should you buy Monopar Therapeutics stock or one of its competitors? MarketBeat compares Monopar Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Monopar Therapeutics include MBX Biosciences (MBX), Regencell Bioscience (RGC), MorphoSys (MOR), Disc Medicine (IRON), and Ultragenyx Pharmaceutical (RARE).

How does Monopar Therapeutics compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Monopar Therapeutics (NASDAQ:MNPR) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

MBX Biosciences currently has a consensus price target of $73.38, indicating a potential upside of 8.19%. Monopar Therapeutics has a consensus price target of $112.08, indicating a potential downside of 5.98%. Given MBX Biosciences' higher possible upside, equities research analysts plainly believe MBX Biosciences is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

MBX Biosciences has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market.

Monopar Therapeutics' return on equity of -12.84% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.21%	-25.29%
Monopar Therapeutics	N/A	-12.84%	-12.57%

In the previous week, MBX Biosciences had 6 more articles in the media than Monopar Therapeutics. MarketBeat recorded 10 mentions for MBX Biosciences and 4 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.47 beat MBX Biosciences' score of -0.07 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Monopar Therapeutics is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

1.8% of Monopar Therapeutics shares are held by institutional investors. 31.1% of MBX Biosciences shares are held by insiders. Comparatively, 9.7% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Monopar Therapeutics beats MBX Biosciences on 10 of the 14 factors compared between the two stocks.

How does Monopar Therapeutics compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Monopar Therapeutics (NASDAQ:MNPR) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by company insiders. Comparatively, 9.7% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

Regencell Bioscience has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market.

Regencell Bioscience's return on equity of 0.00% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Monopar Therapeutics	N/A	-12.84%	-12.57%

In the previous week, Monopar Therapeutics had 4 more articles in the media than Regencell Bioscience. MarketBeat recorded 4 mentions for Monopar Therapeutics and 0 mentions for Regencell Bioscience. Monopar Therapeutics' average media sentiment score of 0.47 beat Regencell Bioscience's score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Regencell Bioscience	Neutral
Monopar Therapeutics	Neutral

Monopar Therapeutics has a consensus target price of $112.08, indicating a potential downside of 5.98%. Given Monopar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Monopar Therapeutics is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

Summary

Monopar Therapeutics beats Regencell Bioscience on 8 of the 12 factors compared between the two stocks.

How does Monopar Therapeutics compare to MorphoSys?

Monopar Therapeutics (NASDAQ:MNPR) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Monopar Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Monopar Therapeutics presently has a consensus price target of $112.08, indicating a potential downside of 5.98%. Given Monopar Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Monopar Therapeutics is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Monopar Therapeutics had 4 more articles in the media than MorphoSys. MarketBeat recorded 4 mentions for Monopar Therapeutics and 0 mentions for MorphoSys. Monopar Therapeutics' average media sentiment score of 0.47 beat MorphoSys' score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Monopar Therapeutics	Neutral
MorphoSys	Neutral

Monopar Therapeutics has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Monopar Therapeutics' return on equity of -12.84% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
MorphoSys	-226.79%	-694.31%	-22.55%

Monopar Therapeutics has higher earnings, but lower revenue than MorphoSys. Monopar Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Summary

Monopar Therapeutics beats MorphoSys on 13 of the 16 factors compared between the two stocks.

How does Monopar Therapeutics compare to Disc Medicine?

Monopar Therapeutics (NASDAQ:MNPR) and Disc Medicine (NASDAQ:IRON) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by insiders. Comparatively, 3.8% of Disc Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A

Monopar Therapeutics currently has a consensus target price of $112.08, indicating a potential downside of 5.98%. Disc Medicine has a consensus target price of $106.00, indicating a potential upside of 36.88%. Given Disc Medicine's higher possible upside, analysts clearly believe Disc Medicine is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Disc Medicine had 17 more articles in the media than Monopar Therapeutics. MarketBeat recorded 21 mentions for Disc Medicine and 4 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.47 beat Disc Medicine's score of 0.43 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Disc Medicine	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Monopar Therapeutics' return on equity of -12.84% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Disc Medicine	N/A	-37.17%	-33.65%

Monopar Therapeutics has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

Summary

Monopar Therapeutics beats Disc Medicine on 9 of the 13 factors compared between the two stocks.

How does Monopar Therapeutics compare to Ultragenyx Pharmaceutical?

Monopar Therapeutics (NASDAQ:MNPR) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Monopar Therapeutics presently has a consensus price target of $112.08, indicating a potential downside of 5.98%. Ultragenyx Pharmaceutical has a consensus price target of $57.82, indicating a potential upside of 123.17%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Monopar Therapeutics has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

In the previous week, Ultragenyx Pharmaceutical had 20 more articles in the media than Monopar Therapeutics. MarketBeat recorded 24 mentions for Ultragenyx Pharmaceutical and 4 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.47 beat Ultragenyx Pharmaceutical's score of 0.36 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	7 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral

Monopar Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Monopar Therapeutics' return on equity of -12.84% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-43.78%

1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Monopar Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Ultragenyx Pharmaceutical	$673M	3.80	-$575M	-$5.84	N/A

Summary

Monopar Therapeutics beats Ultragenyx Pharmaceutical on 10 of the 16 factors compared between the two stocks.

Get Monopar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNPR vs. The Competition

Export

Metric	Monopar Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$798.60M	$3.69B	$7.01B	$13.00B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-62.74	9.02	271.11	25.19
Price / Sales	N/A	1,303.70	597.74	81.69
Price / Cash	N/A	102.35	71.81	50.72
Price / Book	5.78	18.10	13.25	6.22
Net Income	-$13.72M	-$13.25M	$3.45B	$342.66M
7 Day Performance	10.02%	6.24%	4.67%	4.41%
1 Month Performance	14.08%	-3.50%	-1.28%	-1.11%
1 Year Performance	244.04%	61.28%	77.33%	23.99%

Monopar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNPR Monopar Therapeutics	1.2538 of 5 stars	$119.21 -0.8%	$112.08 -6.0%	+244.0%	$798.60M	N/A	N/A	10	News Coverage Upcoming Earnings Analyst Upgrade
MBX MBX Biosciences	1.6144 of 5 stars	$60.06 -2.0%	$66.75 +11.1%	N/A	$2.92B	N/A	N/A	N/A	News Coverage Positive News Earnings Report Analyst Forecast
RGC Regencell Bioscience	0.156 of 5 stars	$5.97 +2.4%	N/A	-61.3%	$2.88B	N/A	N/A	10
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
IRON Disc Medicine	2.2228 of 5 stars	$74.65 +0.1%	$104.44 +39.9%	+33.4%	$2.85B	N/A	N/A	30	Trending News Analyst Forecast Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNPR) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Monopar Therapeutics (MNPR) Competitors

MNPR vs. MBX, RGC, MOR, IRON, and RARE

How does Monopar Therapeutics compare to MBX Biosciences?

Summary

How does Monopar Therapeutics compare to Regencell Bioscience?

Summary

How does Monopar Therapeutics compare to MorphoSys?

Summary

How does Monopar Therapeutics compare to Disc Medicine?

Summary

How does Monopar Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR vs. The Competition

Monopar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Monopar Therapeutics (MNPR) Competitors

MNPR vs. MBX, RGC, MOR, IRON, and RARE

How does Monopar Therapeutics compare to MBX Biosciences?

Do analysts prefer MBX or MNPR?

Which has more volatility & risk, MBX or MNPR?

Is MBX or MNPR more profitable?

Does the media favor MBX or MNPR?

Which has preferable valuation & earnings, MBX or MNPR?

Do insiders and institutionals hold more shares of MBX or MNPR?

Summary

How does Monopar Therapeutics compare to Regencell Bioscience?

Do insiders & institutionals hold more shares of RGC or MNPR?

Which has stronger valuation and earnings, RGC or MNPR?

Which has more risk and volatility, RGC or MNPR?

Is RGC or MNPR more profitable?

Does the media favor RGC or MNPR?

Do analysts prefer RGC or MNPR?

Summary

How does Monopar Therapeutics compare to MorphoSys?

Do institutionals and insiders believe in MNPR or MOR?

Which has more volatility and risk, MNPR or MOR?

Do analysts prefer MNPR or MOR?

Does the media refer more to MNPR or MOR?

Is MNPR or MOR more profitable?

Which has preferable earnings & valuation, MNPR or MOR?

Summary

How does Monopar Therapeutics compare to Disc Medicine?

Do institutionals & insiders believe in MNPR or IRON?

Which has preferable valuation and earnings, MNPR or IRON?

Do analysts recommend MNPR or IRON?

Does the media refer more to MNPR or IRON?

Is MNPR or IRON more profitable?

Which has more volatility and risk, MNPR or IRON?

Summary

How does Monopar Therapeutics compare to Ultragenyx Pharmaceutical?

Do analysts rate MNPR or RARE?

Which has more volatility and risk, MNPR or RARE?

Does the media refer more to MNPR or RARE?

Is MNPR or RARE more profitable?

Do insiders and institutionals hold more shares of MNPR or RARE?

Which has better valuation and earnings, MNPR or RARE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR vs. The Competition

Monopar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools